Olanzapine

Schizophrenia

Olanzapine is used to treat the symptoms of schizophrenia, a mental health condition that can cause disturbed or unusual thinking, loss of interest in life, and strong or inappropriate emotions. It is used for both the initial treatment of symptoms and for long-term maintenance.

Bipolar Disorder

This medication is used to manage symptoms of bipolar I disorder, specifically manic or mixed episodes. It may be prescribed in several ways:

• To treat acute manic or mixed episodes as a short-term therapy.
• As a long-term maintenance treatment to help prevent the recurrence of symptoms.
• Alone or in combination with other medications, such as lithium or valproate.

Depression

When used in combination with fluoxetine, olanzapine is used to treat specific types of depression, including:

• Depressive episodes associated with bipolar I disorder.
• Treatment-resistant depression, which is depression that has not improved after trying at least two other antidepressant medications.

Acute Agitation

An injectable form of olanzapine may be used to treat sudden agitation associated with schizophrenia or bipolar I mania. This form is typically administered by a healthcare professional in a clinical setting.

Olanzapine belongs to a class of medications known as atypical antipsychotics. It works by changing the activity of certain natural substances in the brain to help restore a more normal chemical balance.

While the exact way olanzapine works is not fully understood, it is believed to function by blocking or modifying receptors for two key neurotransmitters:

• Dopamine: This chemical is involved in how the brain processes information and perceives reality. By modulating dopamine activity, the medication helps reduce symptoms such as hallucinations and delusions.
• Serotonin: This chemical plays a major role in regulating mood, sleep, and behavior. Olanzapine's effect on serotonin receptors is thought to help stabilize mood and improve emotional control.

By acting on these and other chemical messengers, olanzapine helps manage the symptoms associated with schizophrenia and bipolar disorder.

Common Side Effects

Many people taking olanzapine experience mild side effects as their body adjusts to the medication. Common symptoms include:

• Drowsiness, dizziness, or tiredness
• Dry mouth and constipation
• Increased appetite and significant weight gain
• Restlessness or a feeling of being unable to sit still
• Pain in the joints or limbs
• Changes in sexual function or menstrual cycles

Serious Side Effects

Some side effects require immediate medical attention. Seek help right away if you experience:

• Uncontrolled movements of the face, tongue, or limbs
• Severe muscle stiffness, high fever, sweating, and rapid heartbeat
• Difficulty swallowing or breathing
• Swelling in the hands, ankles, or feet
• Seizures or sudden confusion
• Signs of high blood sugar, including extreme thirst, frequent urination, and weakness
• Skin rash, hives, or yellowing of the skin or eyes

Boxed Warning: Dementia-Related Psychosis

Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Olanzapine is not approved for the treatment of patients with dementia-related psychosis.

Metabolic Changes

Atypical antipsychotic drugs, including olanzapine, are associated with metabolic changes that may increase cardiovascular risk. These changes include:

• Hyperglycemia and Diabetes: High blood sugar, sometimes leading to serious complications like ketoacidosis or coma, has been reported. Regular monitoring of blood glucose is recommended, especially for those with or at risk for diabetes.
• Dyslipidemia: Changes in cholesterol and triglyceride levels can occur during treatment.
• Weight Gain: Significant weight gain is a common side effect. Healthcare providers typically monitor weight regularly while a patient is taking this medication.

Serious Reactions

Neuroleptic Malignant Syndrome (NMS)

NMS is a rare but potentially fatal condition reported with antipsychotic medications. Symptoms include high fever, muscle stiffness, altered mental state, and irregular pulse or blood pressure. If NMS is suspected, the medication is usually discontinued immediately.

Tardive Dyskinesia

This condition involves involuntary, repetitive body movements, often affecting the face, tongue, or jaw. The risk of developing tardive dyskinesia may increase with long-term use and higher cumulative doses.

Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)

DRESS is a severe and potentially life-threatening systemic reaction. It may present as a rash accompanied by fever and swollen lymph nodes. It can also cause damage to internal organs such as the liver or kidneys.

Other Precautions

• Orthostatic Hypotension: Olanzapine may cause a sudden drop in blood pressure when standing up, which can lead to dizziness, lightheadedness, or fainting.
• Seizures: The medication should be used with caution in individuals with a history of seizures or conditions that lower the seizure threshold.
• Cognitive and Motor Impairment: Because olanzapine can cause significant drowsiness (somnolence), it may impair the ability to drive or operate heavy machinery.
• Body Temperature Regulation: Antipsychotics can interfere with the body's ability to reduce its core temperature. Caution is advised during strenuous exercise, exposure to extreme heat, or dehydration.
• Difficulty Swallowing: Use of this medication has been associated with esophageal dysmotility and aspiration (food or liquid entering the lungs).

Pregnancy

If you are pregnant or planning to become pregnant, discuss the risks and benefits of olanzapine with your healthcare provider. Using antipsychotic medications like olanzapine during the third trimester of pregnancy may cause problems in the newborn after delivery.

Symptoms reported in newborns exposed to these medications include:

• Agitation or irritability
• Muscle stiffness or weakness
• Tremors
• Sleepiness
• Difficulty breathing
• Feeding problems

Some newborns may recover within hours or days without specific treatment, while others may require a hospital stay. Do not stop taking your medication without consulting your doctor, as stopping treatment may cause your symptoms to return.

Breastfeeding

Olanzapine passes into breast milk. Because of the potential for side effects in a nursing infant, healthcare providers generally advise caution. Talk to your doctor about the risks and benefits of breastfeeding while taking this medication to determine the best way to feed your baby.

Oral Formulations

Olanzapine is provided in the following oral forms:

• Tablets: Standard oral tablets taken by mouth.
• Orally disintegrating tablets: These are designed to be placed on the tongue to dissolve and can be swallowed without water.
• Combination capsules: A formulation that contains both olanzapine and fluoxetine in a single capsule.

Injectable Formulations

Olanzapine is available as an injection for administration into a muscle by a healthcare professional:

• Immediate-release injection: A fast-acting form typically used for short-term treatment.
• Extended-release injectable suspension: A long-acting form that releases the medication slowly over a period of weeks.

FDA Approval and Indications

Olanzapine is approved by the U.S. Food and Drug Administration (FDA) for the treatment of schizophrenia and bipolar I disorder, including acute manic or mixed episodes. It is also approved for use in combination with fluoxetine for the treatment of depressive episodes associated with bipolar I disorder and for treatment-resistant depression.

Boxed Warning

The FDA has issued a boxed warning for olanzapine regarding its use in elderly patients with dementia-related psychosis. Clinical trials have demonstrated that elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Olanzapine is not approved for the treatment of patients with dementia-related psychosis.

REMS and Safety Requirements

The long-acting injectable formulation of olanzapine is subject to a Risk Evaluation and Mitigation Strategy (REMS) program. This regulatory requirement is due to the risk of post-injection delirium sedation syndrome (PDSS), a serious condition that can occur after administration. Under this program, the medication must be administered in a registered healthcare facility, and patients must be monitored by a healthcare professional for at least three hours after each injection.

Pediatric Regulatory Status

The FDA has approved olanzapine for use in adolescents (ages 13 to 17) for the treatment of schizophrenia and bipolar I disorder. Regulatory labeling indicates that healthcare providers should consider the increased risk of weight gain and lipid changes in the pediatric population compared to adults when prescribing this medication.

Weight Gain and Appetite Changes

Weight gain is a common and often significant side effect of olanzapine. This medication can cause a noticeable increase in appetite, leading to more frequent eating or larger portions.

Monitoring and Risks

• Regular Monitoring: Healthcare providers typically track weight and body mass index (BMI) regularly throughout treatment to manage these changes.
• Metabolic Impact: Significant weight gain from olanzapine may be accompanied by increases in blood sugar, cholesterol, and triglyceride levels.
• Age Factors: Teenagers taking olanzapine may be more susceptible to gaining weight and having higher increases in fat levels in the blood compared to adults.

Managing weight while taking olanzapine often involves lifestyle adjustments, such as maintaining a healthy diet and engaging in regular physical activity. It is important to discuss any rapid or concerning weight changes with a doctor.